Introduction 46
According to the latest United Nations Joint Programme on HIV/AIDS estimates 47 Because of the lack of data on the use of TDF in pregnancy and concerns 53 over possible bone toxicity, US guidelines recommend that TDF-based HAART 54
should be used only after careful considerations of alternatives (8). However, for 55 women who were already treated by TDF prior to pregnany, EACS guidelines 56 recommend to continue the TDF treatment during pregnancy. Thus in these 57 therapeutic drug monitoring data (TDM) data, some women were under TDF during 58 their pregnancy in the first, second and third trimester. 59 TDF is already taken during pregnancy at the same dose as in adults although 60 physiological changes associated with pregnancy can lead to significant variations in 61 pharmacokinetics (modified absorption, distribution and elimination).
No 62 pharmacokinetic data on the use of TDF before the 38 th week of pregnancy are 63 available. Two studies restricted to late pregnancy and labour suggest that TFV 64 exposure is lower than nonpregnant adult exposure (9, 16) . 65
In this work, a population pharmacokinetic study was performed during 66 pregnancy, at delivery, and out pregnancy; in order to investigate TFV 67 pharmacokinetics all pregnancy long. 
Patients-treatments 73
The population included nonpregnant women, pregnant women and women 74 on the day of delivery receiving oral tenofovir for treatment of HIV infection and 75 whose antiretroviral drug plasma concentrations were monitored on a routine basis. 76
Tenofovir was administered chronically as a 300-mg once-daily. For each woman, 77 the time elapsed between administration and sampling times, time of dosing, body 78 weight (BW), age and weeks of gestation were carefully recorded. Ethics committee 79 approval and patient consent are not compulsory in France in order to use 80 therapeutic drug monitoring data, and thus they were not obtained. 81
82

Analytical method 83
The tenofovir assay was performed according to a previously published 84 method (10) with an LOQ, interassay precision, and bias of 0.01 mg/l, 9.6, and 85 
11
Population pharmacokinetic modelling 109
One and two compartments models were tested. Tenofovir concentrations 110 below the LOQ were set to half of the LOQ (2). Several error models were 111 investigated (i.e. multiplicative and additive error models) to describe residual 112 variability. Exponential model was used for between-subject variability (BSV). Only 113 significant BSVs on pharmacokinetic parameters were retained. The covariates 114 tested were women age and bodyweight on the day of sampling, labour status and 115 pregnancy status. 116
The effect of each patient covariate was systematically tested via generalized 117 additive modeling on the basic model. 118
• Continuous covariates (CO) : age and bodyweight, were tested according to 119 the following equation, using CL for example,
where θ CL is the typical value of clearance for a patient with the median 121 covariate value and CL CO β is the estimated influential factor for the continuous 122 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from 6 covariate. When a covariate was missing, it was set to the median value from 123 all the other women. 124
• Delivery was considered as a binary covariate and its influence was tested as 125 follows:
where DEL =1 if delivery and 0 otherwise, and 126 CL DEL β is the estimated influential factor for delivery. 127
• The influence of pregnancy on TFV PK parameters was investigated using 128 two different approaches: 129
130
(i) with a continuous relation between clearance and gestational age as 131 follows : 132
Where PREG =1 if pregnant or parturient and 0 otherwise, and CL GA β is the estimated 134 influential factor for pregnancy. 135 
Demographic data 153
Data from 186 women (156 non pregnant and 46 pregnant women) were available 154 for TFV pharmacokinetic evaluation. Table 1 summarizes the patients' 155 characteristics. At sampling times, among all non pregnant women 66 % were co-156 treated with a protease inhibitor (PI) (including 49.1% lopinavir/r), 76.7% were co-157 treated with a nucleoside reverse transcriptase inhibitor (NRTI) and 14,9% were co-158 treated with non-nucleoside reverse transcriptase inhibitors(NNRTI). Among pregnant 159 women 85 % were co-treated with a PI (including 66% lopinavir/r), 89.6% were co-160 treated with a NRTI and 12.3% were co-treated with NNRTI. 161
162
Population pharmacokinetics 163
A total of 326 TFV concentrations were used for the pharmacokinetic analysis, 164 among these concentrations 52 samples were obtained during pregnancy at different 165 gestational ages (6 concentrations in the first trimester of pregnancy, 18 in the 166 second trimester of pregnancy and 28 in the third trimester of pregnancy) and 25 on 167 the day of delivery (70 women had more than one sample and the maximum number 168 of sample per women was 7). The range of sampling times was 0.8-28.8 hours after 169 the dose. Two TFV concentrations were lower than the LOQ, so they were set to half 170 of the LOQ. All plasma samples were collected at steady state. A two compartment 171 model with first order absorption and elimination best described the data. were apparent parameters and F is the unknown bioavailability. The available data 176
were not sufficient to estimate between-subject variability for k a , Q/F, and V p /F. and 177 fixing the variance of these random effects to zero had no influence on the goodness-178 for-fit criteria. 
estimated. 204
Women TFV-concentrations after a 300mg TDF administration 205 Table 3 summarizes area under the curve (AUC) of TFV obtained after a 300 mg 206 daily dose of TDF for non pregnant and pregnant women compared to previous 207 studies in adult (4, 3, 14) . 208
209
Simulations of doses in pregnant women 210
Pregnant women AUCs and Cmin were simulated following an administration of two 211 tablets of TDF (600mg TDF, 272mg TFV) (Table 4) . In the present work, tenofovir women pharmacokinetics was satisfactorily 216 described by a 2-compartmental model. The following observations support the 217 validity of this model: i) the population predicted concentrations were well correlated 218 with observed concentrations and ii) the population model was validated thanks to 219 the VPC method. Moreover, pharmacokinetic parameters obtained from our 220 population model were close to the values reported in previous studies (Table 3) . 221
Pharmacokinetics of tenofovir in pregnant women was described in two 222 TFV after a single dose at the start of labour, the two studies concluded that a 225 maternal 600 mg TDF administration at the start of labour produces the same 226 concentrations as 300mg administration in other adults (9, 16). A more recent study 227 confirmed the necessicity of an increased dose of TDF during labor (7), 228 administration of 600 mg and 900 mfg of TDF was safe and well tolerated in HIV-229 infected women in active labor or prior to caesarean section. . In our study, women 230 were treated by TDF during their pregnancy and during delivery by the same 300 mg 231 TDF dose, we confirmed the increase of clearance in parturient women and so the 232 necessity to increase TDF dose in these women. pharmacokinetics not only in late pregnancy but from week 2 to week 41 of gestation, 237 during labour, and out of pregnancy. We observed that TFV clearance was about 238 39% higher in women during pregnancy compared to non pregnant women. 239
Tenofovir is primarily excreted by the kidney by a combination of glomerular filtration 240 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from and active tubular secretion system with ~70%-80% of the dose excreted unchanged 241 in the urine (15). In pregnancy, glomerular filtration rate (GFR) and effective renal 242 plasma flow increase to levels 50% to 80% above non pregnant levels (1, 6). This 243 increase occurs shortly after the conception and persists throughout the second 244 trimester (6). In our study, the increased clearance observed during pregnancy could 245 be explained by these physiological changes in GFR during pregnancy. However, no 246 information was available about serum creatinin levels or GFR in our population to 247 confirm it. Besides the glomerular filtration tenofovir undergoes active tubular 248 secretion dependent on hOAT1, hOAT2 and MRP4 (15). Very little is known 249 regarding the effect of pregnancy on these transporters (1). 250
In our study, women age ranged from 16 to 62 and this wide range allowed us 251 to describe the age effect on tenofovir clearance. Indeed tenofovir clearance seemed 252 to decrease slightly but significantly with age, which is in agreement with the pattern 253 of the GFR decline with aging as described in the KDOQI (13). The subject age 254 range was higher for non pregnant women (62 years vs. 43 years) but the effect of 255 pregnancy was observed with or without the older non pregnant women. 256
Lopinavir/ritonavir co-treatment had no effect on the apparent clearance of tenofovir, 257 contrary to previous studies. 258
Since no relationship between TFV plasma concentration and virologic 259 response has been established, a reasonable goal for TFV dosing during pregnancy 260 is to achieve plasma exposure in pregnant women equivalent to that observed in 261 nonpregnant adults treated with the standard 300mg TDF dose. In our study, non 262 pregnant women C min were similar to those reported in non pregnant adult (Table 3) , 263 their mean TFV exposure expressed as AUCs were slightly lower but not significantly 264 different from non pregnant adult values (2.4 vs. 2.65, p=0.3). Since TDF is only 265 available in 300 mg tablets, we simulated pregnant women AUCs and Cmin following 266 an administration of two tablets of TDF (600mg TDF, 272mg TFV). It appears that 267 pregnant women exposure to TFV is low after the administration of one tablet of TDF 268 but may be too high after the administration of two tablets (table 4) . 269
In conclusion, women tenofovir pharmacokinetics was accurately described by 270 a 2-compartment model. Tenofovir apparent clearance was increased by 39% in 271 pregnant women. In order to obtain an exposure similar to the known exposure in 272 adults and guarantee similar trough concentrations as expected in adult, a tenofovir 273 dose escalation should be considered for women from the second trimester to 274 delivery. Since limited clinical experience at doses higher than the therapeutic 300 275 mg TDF dose, further investigations are needed. 
